When physician-scientist David Fajgenbaum and his colleagues launched the nonprofit Every Cure, they set out to answer a deceptively simple question: how many existing drugs could help patients with rare diseases that currently have no effective treatment?
Twelve hours after the group publicly highlighted its latest push to scale up that search, the effort is drawing attention because it challenges how medicine typically approaches rare conditions: one drug, one disease, developed at great cost over many years. Instead, Every Cure is trying to systematically repurpose already-approved medicines, potentially shortening the path from lab to bedside for people who have been waiting for decades.
The initiative and its promise for rare disease patients were described in recent coverage by CNBC, which has closely followed the nonprofit’s work. A separate roundup in Stat, focused on rare disease drug approvals, underscores how central the search for new options has become in this corner of medicine.
A nonprofit built around drug repurposing
Every Cure is structured as a nonprofit devoted to drug repurposing — the practice of finding new uses for existing, approved medicines. According to CNBC’s reporting, the organization is working to systematically scan the universe of available drugs and match them to diseases that lack good treatments, with a particular emphasis on rare conditions.
Drug repurposing is not new; individual drugs have occasionally been found to help in unexpected ways when doctors or researchers notice patterns in patients. What distinguishes Every Cure, as described in CNBC’s account, is the attempt to make this process comprehensive and data-driven rather than accidental.
The group’s work is rooted in Fajgenbaum’s own experience as a patient with a rare disease. While those personal details go beyond what current reporting fully documents, CNBC notes that his clinical and research background informs the nonprofit’s focus on conditions that are often overlooked by large pharmaceutical companies because of their small patient populations.
Why rare diseases are at the center
Across both CNBC’s piece on Every Cure and Stat’s broader look at rare disease drugs, three words recur: disease, drug, rare. That repetition reflects a shared focus in current coverage: the gap between the number of known rare diseases and the far smaller number of available treatments.
Stat’s reporting, which surveys recent regulatory activity, highlights that regulators such as the U.S. Food and Drug Administration are still approving new medicines specifically developed for rare conditions. Those approvals show that traditional drug development is continuing. But they also underscore how slow and expensive that route can be, especially when each new therapy is tailored to a small group of patients.
Every Cure’s model, by contrast, starts with medicines that regulators have already cleared as safe and effective for at least one use. CNBC notes that by looking for additional disease matches for those drugs, the nonprofit is trying to bypass some of the earliest, riskiest phases of development. For patients with serious, poorly treated rare diseases, that could mean new options arrive faster — if the matches prove to be medically sound.
How the approach could change treatment
The core of Every Cure’s strategy, as described by CNBC, is to treat the existing drug arsenal as a shared resource rather than a fixed set of one-to-one solutions. In practice, that means:
- Starting from approved drugs. These medicines already have safety data and manufacturing in place.
- Systematically scanning diseases. The nonprofit’s work is reported to focus heavily on rare conditions, where unmet need is highest.
- Prioritizing repurposing candidates. The goal is to identify which drug–disease combinations look promising enough to justify further clinical study.
If successful, this could alter the treatment landscape for rare diseases in several ways:
- More options from existing tools. Patients might gain access to therapies drawn from shelves of already-approved drugs rather than waiting for entirely new compounds.
- Potentially shorter timelines. Because safety profiles are better understood for existing medicines, the path from hypothesis to clinical testing may be shorter than for first-in-class drugs.
- Different economics. Repurposed drugs are often older and sometimes off-patent, which can affect pricing and commercial incentives. While current coverage does not deeply detail these financial dynamics, CNBC’s framing suggests that a nonprofit model is partly meant to work around the limited commercial appeal of small patient populations.
At the same time, the reporting makes clear that repurposing is not a shortcut around scientific rigor. Even if a drug is safe in one setting, it still needs to be tested for effectiveness and appropriate dosing in a new disease. That means patients and clinicians should not expect immediate, widespread changes in care based solely on computational matches or early hypotheses.
What is known — and what remains uncertain
The available coverage supports several concrete points about Every Cure’s work and its potential impact:
- The focus is on rare diseases. Both CNBC’s direct reporting on the nonprofit and Stat’s broader context on rare disease drugs emphasize that this is where unmet need is most acute.
- The tool is drug repurposing. Every Cure is not primarily developing new molecules; it is trying to find new uses for existing ones.
- The aim is to change treatment options. CNBC reports that the group’s leaders believe their approach could materially alter how rare diseases are treated, if promising drug–disease matches can be validated.
Several important questions, however, are not yet fully answered in the public reporting:
- Scale and speed. Current articles do not quantify how many drug–disease matches Every Cure has identified so far, or how quickly those candidates could move into clinical testing.
- Regulatory path. While Stat discusses an FDA approval for a rare disease drug in a separate context, it does not spell out how regulators are likely to handle large numbers of repurposing proposals from nonprofits.
- Access and cost. Neither source provides detailed evidence on how repurposed treatments, if validated, would be priced or reimbursed, especially when older drugs are involved.
These gaps do not undermine the reported core: that Every Cure is actively pursuing a systematic repurposing strategy and that observers see it as a potentially significant development for rare disease treatment. They do, however, mark the boundaries of what can be said with confidence at this stage.
Human stakes behind the strategy
While the current coverage focuses more on the model than on individual patient stories, the stakes are implicit. Rare diseases, by definition, affect relatively small numbers of people, but collectively they touch millions of families worldwide. Many of those conditions have no approved treatment at all.
CNBC’s reporting on Every Cure frames the nonprofit’s work as an attempt to address that absence not by waiting for a wave of new drugs, but by looking again at medicines already in circulation. Stat’s mention of a recent FDA approval for a rare disease drug, in a broader news roundup, adds weight to the idea that even a single new option can matter greatly to a small patient community.
For patients and caregivers, the promise of repurposing is not that it guarantees a cure, but that it opens a new line of possibility. A drug originally designed for one disease might, after careful study, offer partial relief or disease control for another that has long gone untreated. The reporting so far stops short of documenting specific success stories tied directly to Every Cure’s current projects, but it makes clear that this is the kind of outcome the nonprofit is working toward.
What to watch next
In the coming days and weeks, the most concrete developments to watch will be how Every Cure translates its repurposing framework into specific, testable drug–disease pairs. CNBC’s focus on the group’s launch and strategy suggests that the next phase will likely involve public announcements of particular candidates and, eventually, clinical trials designed to test them.
Readers can also look for follow-up reporting from outlets such as CNBC and Stat on how regulators respond to these efforts, especially if Every Cure begins to present data supporting new uses for older drugs. Any movement toward formal studies, regulatory submissions, or partnerships with academic medical centers would be key indicators that the nonprofit’s approach is shifting from concept to practice.
For now, the evidence-based bottom line is that Every Cure has put drug repurposing for rare diseases on the agenda in a new way. The scale of its impact will depend on how many of its hypotheses survive the scrutiny of clinical testing and regulatory review — and how quickly those results can reach the patients who have the most to gain.
